Glenmark Pharmaceutical (Glenmark), a manufacturer of generic formulation products and API, witnessed a rise in share price on Wednesday after the Glenmark Generics, the subsidiary of the company has been granted final approval for its abbreviated new drug application (ANDA) from the United States Foods and Drug Administration (USFDA). The approval is for Omeprazole Delayed Release Capsules, their generic version of Prilosec by AstraZeneca.
Shares of the company are trading at Rs 745.10, up Rs 16.5, or 2.26% at the Bombay Stock Exchange (BSE) on Wednesday at 11:49 a.m.
The scrip has touched an intra-day high of Rs 746 and low of Rs 732.10. The total volume of shares traded at the BSE is 20,980.